Introduction
============

Molecularly based choice of care for solid tumors was pioneered in the treatment of breast cancer. In addition to classic pathological information, such as tumor size, number of involved lymph nodes, presence or absence of metastasis, and histological grade, treatment selection today requires information about the expression of ER, PgR, and HER2. Expression of ER and/or PgR is not only a good prognostic factor but a well-characterized predictive factor for benefit from endocrine therapies. In contrast, HER2 overexpression is a poor prognostic factor, but does predict benefit from HER2-targeting drugs. The new concept of intrinsic subtypes created based on complementary deoxyribonucleic acid (cDNA) microarray data has been introduced to clinical care.[@b1-bctt-7-111] Nevertheless, subtype classification is actually done by the protein-expression pattern of ER, PgR, HER2, and Ki67 in combination, mainly measured with immunohistochemistry, because this method provides high concordance with authentic microarray-determined intrinsic subtype and is much less expensive.[@b2-bctt-7-111] It can therefore be said that molecularly based choice of care has seen little progression in the 21st century, and that patients with breast cancer require more sophisticated molecular markers able to deliver more individualized and effective care.

The PI3K pathway is one of the most characterized signaling pathways with relevance to oncogenic properties in a variety of malignancies. In particular, breast cancer tumorigenesis is believed to depend on the PI3K pathway. This is based on the fact that the majority of cases of this disease harbor at least one molecular mechanism that potentially enhances the pathway. These PI3K-enhancing mechanisms include mutations of the *PI3K* gene, more specifically *PIK3CA* gene mutations. First discovered in 2004 in various solid tumors, including breast cancer,[@b3-bctt-7-111] these mutations have the potential to become a clinically useful biomarker, because they 1) are gain-of-function mutations of molecules located on an important signaling pathway, 2) are found at high frequency, and 3) are easy to measure (present or absent).

In this review, we focus on the many studies that have explored the prognostic value and therapeutic relevance of *PIK3CA* mutations since their discovery.

Physiology of PI3K
==================

Structure of PI3K
-----------------

PI3K is grouped into three classes (I--III) based on their structure and substrate specificity. Class I PI3K is further categorized into class IA and IB ([Figure 1](#f1-bctt-7-111){ref-type="fig"}). Class IA PI3K is the class most closely implicated in cancer, and is referred to in this review simply as "PI3K" ([Figure 1](#f1-bctt-7-111){ref-type="fig"}). PI3K is constituted of a p110 catalytic domain and p85 regulatory domain. There are three isoforms of p110, namely p110α (encoded by *PIK3CA*), p110β, and p110δ. While p110δ is expressed almost exclusively in leukocytes, p110α and p110β are expressed ubiquitously in all types of cells.[@b4-bctt-7-111] In humans, PI3K regulatory subunit 1 (*PIK3R1*), *PIK3R2*, and *PIK3R3* code p85α (or its splicing variant p55α or p50α), p85β, and p55γ, respectively.[@b4-bctt-7-111]

PI3K signalling
---------------

On RTK activation, p85 interacts directly with RTK or via adaptor proteins, and the resulting PI3K is recruited to the membrane ([Figure 2](#f2-bctt-7-111){ref-type="fig"}).[@b4-bctt-7-111] In addition to RTKs, RAS, which triggers MAPK pathways, can also directly bind to and activate PI3K ([Figure 2](#f2-bctt-7-111){ref-type="fig"}).[@b5-bctt-7-111] On the cell membrane, inhibitory regulation of p85 to 110 is canceled, and PI3K becomes active as a kinase. Subsequently, PI3K catalyzes the conversion of PIP~2~ to PIP~3~.[@b4-bctt-7-111],[@b5-bctt-7-111] In physiological conditions, the intracellular concentration of PIP~3~ is meticulously regulated by PTEN, which catalyzes the conversion of PIP~3~ to PIP~2~ [@b4-bctt-7-111],[@b5-bctt-7-111] As a result, PTEN functions as a negative regulator of PI3K. PIP3 is further recognized by AKT and PDPK1.[@b4-bctt-7-111],[@b5-bctt-7-111] Connection of PIP~3~ to PDPK1 and AKT allows the physical interaction of PDPK1 and AKT, which leads to activation of AKT by phosphorylation of the T308 residue.[@b4-bctt-7-111] Maximal activation of AKT requires phosphorylation of the S473 residue by PDPK2, and mTORC2 mainly works as PDPK2.[@b4-bctt-7-111] AKT phosphorylates several cellular proteins, GSK3, FOXO1, MDM2, and BAD ([Figure 2](#f2-bctt-7-111){ref-type="fig"}).[@b5-bctt-7-111] In addition, AKT phosphorylates and inactivates TSC2, which allows RHEB to activate mTORC1 ([Figure 2](#f2-bctt-7-111){ref-type="fig"}).[@b5-bctt-7-111] These AKT signalings result in enhanced growth, antiapoptosis, cell-cycle progression, and translation ([Figure 2](#f2-bctt-7-111){ref-type="fig"}).[@b4-bctt-7-111],[@b5-bctt-7-111]

PI3K-enhancing mechanisms in breast cancer
==========================================

PI3K alteration
---------------

### *PIK3CA* mutations

Somatic mutations of *PIK3CA* coding p110α in various solid malignancies were first reported in 2004.[@b3-bctt-7-111] Although the initial study reported that the frequency of mutations was relatively low in breast cancer (10%), later studies revealed that breast cancer was in fact among the most frequently affected cancers (\~30%) ([Table 1](#t1-bctt-7-111){ref-type="table"}). The majority of *PIK3CA* somatic mutations are located in two "hot spots": E542K or E545K in exon 9, and H1047R or H1047L in exon 20.[@b3-bctt-7-111] Both types of mutation were shown to be gain-of-function mutations and to have transforming capacity.[@b6-bctt-7-111],[@b7-bctt-7-111] Exon 9 mutations are located in the helical domain of p110α, and are considered to enable p110α to escape the inhibitory effect of p85 via the Src-homology 2 (SH2) domain. Exon 20 mutations are located near the activation loop in the kinase domain, but the mechanism by which they promote constitutive PI3K signaling remains unclear.[@b8-bctt-7-111],[@b9-bctt-7-111]

### *PIK3CA* amplification

Preceding the discovery of *PIK3CA* mutations, gene amplification of *PIK3CA* was reported in various malignancies, including approximately 10% of cases of breast cancer.[@b4-bctt-7-111],[@b10-bctt-7-111] Like *PIK3CA* mutations, *PIK3CA* amplification has been shown to lead to increased PI3K activity.[@b11-bctt-7-111]

### *PIK3R1* mutation/low expression

The *PIK3R1* gene product p85α appears to play a tumor-suppressor role by stabilizing p110α.[@b12-bctt-7-111] *PIK3R1* mutations have been found in breast cancer, although with much lower occurrence than *PIK3CA* mutations (\~3%).[@b12-bctt-7-111],[@b13-bctt-7-111] *PIK3R1* mutations are located at the inter-SH2 domain, which is required for connection of p85α to p110α. They are believed to cancel the inhibitory effect of p85α on p110α, eventually leading to PI3K hyperactivation.[@b5-bctt-7-111] In contrast with the rarity of *PIK3R1* mutations in breast cancer, reduced *PIK3R1* messenger ribonucleic acid (RNA) expression, defined as \<0.5-fold of normal breast tissue, is reported to be frequent (183 of 458 cases \[61.8%\]).[@b12-bctt-7-111]

Other PI3K-enhancing mechanisms
-------------------------------

### *HER2* amplification

As described earlier, PI3K is activated by being connected with RTK directly or indirectly via adaptor proteins. Gene-amplified *HER2* is the best-characterized RTK with regard to breast cancer tumorigenesis. While HER2 can theoretically form four different types of dimer (with HER1, HER2, HER3, or HER4), the HER2/HER3 heterodimer is thought to be the most mitogenic and transforming.[@b14-bctt-7-111]--[@b17-bctt-7-111] HER3 is distinguished from other HER family members by two peculiar characteristics: it lacks tyrosine-kinase activity on its own, and it contains at least six docking domains for p85 of PI3K.[@b18-bctt-7-111] These properties allow HER3 to function as a scaffold protein to efficiently trigger the PI3K pathway. In fact, a study has suggested that breast cancer cell lines expressing both HER2 and HER3 appear to have a higher degree of AKT phosphorylation.[@b19-bctt-7-111] Other studies have suggested that the HER2/HER3/PI3K complex and subsequent PI3K--AKT signaling pathway play central roles in cell proliferation in *HER2*-amplified cells.[@b20-bctt-7-111],[@b21-bctt-7-111]

### PTEN dysfunction

Malignant tumors frequently show dysfunction of PTEN. While PTEN mutations are relatively uncommon in breast cancer (\<5%), PTEN protein loss is frequent (\~30%).[@b22-bctt-7-111],[@b23-bctt-7-111] This loss is reported to be caused by various mechanisms, such as promoter methylation, loss of heterozygosity, and regulation at the RNA or protein level.[@b22-bctt-7-111],[@b23-bctt-7-111]

### *AKT1* mutation

*AKT1* mutations (E17K) have been found in 1.4%--8% of breast cancers.[@b12-bctt-7-111],[@b23-bctt-7-111],[@b24-bctt-7-111] Although this low frequency precludes the drawing of any definitive answers, a large-scale genotyping effort (547 breast tumor and 41 breast cancer cell lines) revealed that *AKT1* mutations were exclusively observed in tumors expressing both ER and PgR.[@b23-bctt-7-111]

Relationship between PI3K-enhancing mechanisms in breast cancer
---------------------------------------------------------------

Molecular changes on the same signaling axis can be mutually exclusive in malignant tumors. If two genes are mutated in a mutually exclusive fashion in a certain type of cancer, it is likely that they provide the same selective pressure for clonal expansion. As an example, somatic mutations of *EGFR* and *K-RAS* and *ALK* rearrangements have been consistently shown to be mutually exclusive in lung adenocarcinoma.[@b25-bctt-7-111] As shown later in this review, however, *PIK3CA* mutations and *HER2* amplification often coexist. An early study demonstrated that *PIK3CA* mutations and PTEN loss, another PI3K-enhancing change frequently observed in breast cancer, were present in a nearly mutually exclusive fashion.[@b26-bctt-7-111] More recent studies, however, denied this mutual exclusivity of the two molecular changes.[@b27-bctt-7-111],[@b28-bctt-7-111] *PIK3CA* mutations and gain of copy number of *PIK3CA* and PTEN loss and *PTEN* mutations have also been reported to coexist.[@b11-bctt-7-111],[@b23-bctt-7-111],[@b28-bctt-7-111],[@b29-bctt-7-111] On the other hand, *PIK3CA*, *PTEN*, *AKT1*, and *PIK3R1* mutations are reported to be mutually exclusive, although the low frequency of the latter three limits the reliability of the finding.[@b12-bctt-7-111],[@b23-bctt-7-111] One study showed that *PIK3CA* mutations and reduced *PIK3R1* messenger RNA expression are mutually exclusive.[@b12-bctt-7-111]

Collectively, while mutual exclusivity is maintained between some PI3K-enhancing molecular changes, three major types -- *HER2* amplification, *PIK3CA* mutations, and PTEN loss -- appear to coexist, indicating that none of these three mechanisms may be sufficient to keep PI3K-pathway activity at a high oncogenic level.

*PIK3CA* mutations and clinicopathological factors
==================================================

Correlation with hormone receptors and HER2
-------------------------------------------

Among studies, the correlation of *PIK3CA* mutations with hormone-receptor status has received the most extensive investigation. A meta-analysis involving 26 studies found significant association between *PIK3CA* mutations and ER and PgR expressions (for ER, odds ratio \[OR\] 1.92, 95% confidence interval \[CI\] 1.65--2.23; for PgR, OR 1.88, 95% CI 1.61--2.20).[@b30-bctt-7-111]

In terms of HER2 status, an early study showed a positive correlation between *PIK3CA* mutation and HER2 overexpression.[@b26-bctt-7-111] However, subsequent studies demonstrated no association of *PIK3CA* with HER2 status,[@b31-bctt-7-111],[@b32-bctt-7-111] or rather an association with HER2-negativity.[@b27-bctt-7-111],[@b33-bctt-7-111]--[@b36-bctt-7-111]

Further, some studies found associations of *PIK3CA* mutations with good prognostic features, such as lower histological grade,[@b33-bctt-7-111]--[@b35-bctt-7-111],[@b37-bctt-7-111]--[@b39-bctt-7-111] non-triple-negative subtype,[@b40-bctt-7-111] luminal A subtype,[@b37-bctt-7-111] smaller tumor size,[@b27-bctt-7-111],[@b35-bctt-7-111],[@b39-bctt-7-111] and lower levels of Ki67.[@b37-bctt-7-111]

Overall, it appears safe to say that *PIK3CA* mutations are most likely found in luminal-type (HR-positive/HER2-negative) tumors, in particular those with markers indicating less aggressive tumor characteristics.

Correlation of PIK3CA mutations with phosphorylated downstream proteins
-----------------------------------------------------------------------

Hot-spot *PIK3CA* mutations were found to be gain-of-function mutations, and resulted in higher phosphorylation of downstream signaling molecules on the PI3K pathway in preclinical studies.[@b6-bctt-7-111],[@b7-bctt-7-111] Several studies tried to address the clinical relevance of this higher phosphorylation using tumors obtained from patients. However, results of the correlation of *PIK3CA* mutations and level of phosphorylated AKT (Ser473 or Thr308), the most frequently used biomarker of PI3K-pathway activity, are controversial, with some studies showing positive correlation[@b31-bctt-7-111],[@b38-bctt-7-111],[@b41-bctt-7-111] and others showing no correlation.[@b27-bctt-7-111],[@b42-bctt-7-111],[@b43-bctt-7-111] Results of studies correlating *PIK3CA* mutations with phosphorylated mTOR (p-mTOR) expression have also been inconsistent, with positive correlations in some[@b42-bctt-7-111] but not others.[@b38-bctt-7-111] A study utilizing a reverse-phase protein array, which enables more comprehensive protein analysis, failed to show a difference between *PIK3CA*-mutant tumors and *PIK3CA* wild-type tumors in the phosphorylation of AKT, GSK3, mTOR, or p70S6K.[@b23-bctt-7-111] Of note, phosphorylation of AKT, mTOR, and p70S6K was significantly higher in PTEN-low than PTEN-high tumors.[@b23-bctt-7-111]

Based on these inconsistent results, correlation between *PIK3CA* mutations and downstream protein activation must be considered inconclusive, at least in clinical specimens. These inconsistent results may be due to the lack of standardization in detection methods for the phosphorylated proteins and possible variation in the amount of phosphorylated residue preserved depending on sample condition.

Prognostic and predictive values of *PIK3CA* mutations
======================================================

Prognostic factor vs predictive factor
--------------------------------------

A number of studies have evaluated the clinical relevance of PI3K mutations, some of which asked if they have prognostic or predictive value, or both. Prognostic and predictive factors are often confused. The original definition of a prognostic biomarker is a marker that provides information on the likely course of the cancer disease in an untreated individual. In contrast, predictive biomarkers are defined as markers that can be used to identify subpopulations of patients who are most likely to respond to a given therapy. Distinguishing these terms thus requires the use of biomarker-positive and -negative subgroups and treated and untreated subgroups ([Figure 3](#f3-bctt-7-111){ref-type="fig"}). However, if time-independent end points such as response rate (RR) and pathologic complete response (p-CR) rate are considered, a cohort in which all patients are treated with a given therapy will provide a predictive biomarker, because p-CR rate as an example in untreated patients would have been 0, regardless of the biomarker status.

Prognostic value of PIK3CA mutations
------------------------------------

### Prognostic value for early breast cancer: recurrence-free survival

Although few studies solely showed prognostic value of *PIK3CA* mutations for recurrence-free survival (RFS) with statistical significance, many of these indicated the tendency for patients with mutant *PIK3CA* to have better RFS ([Table 1](#t1-bctt-7-111){ref-type="table"}). In fact, one meta-analysis involving five studies listed in [Table 1](#t1-bctt-7-111){ref-type="table"}[@b27-bctt-7-111],[@b31-bctt-7-111],[@b33-bctt-7-111],[@b39-bctt-7-111],[@b40-bctt-7-111] demonstrated a significant correlation of *PIK3CA* mutation with better RFS (hazard ratio \[HR\] 0.76, 95% CI 0.59--0.98; *P*=0.03).[@b30-bctt-7-111] Another meta-analysis involving six studies[@b31-bctt-7-111],[@b33-bctt-7-111],[@b35-bctt-7-111],[@b39-bctt-7-111],[@b44-bctt-7-111],[@b45-bctt-7-111] reached essentially the same conclusion (HR for disease-free survival \[DFS\] 0.72, 95% CI 0.57--0.91; *P*=0.006).[@b46-bctt-7-111]

It remains unclear, however, whether *PIK3CA* mutation itself biologically affects tumor character or is just a product of confounding effects between *PIK3CA* mutations and other good prognostic factors, such as ER positivity, HER2 negativity, lower Ki67, and lower histological grade, as described earlier. In addition, the great majority of patients involved in these meta-analyses received perisurgical treatment. Because any treatments could potentially affect the natural consequence of the disease, their involvement precludes evaluation of "pure" prognostic value of *PIK3CA* mutations. In fact, a recent study that collected tumor samples from ER-positive postmenopausal patients who had participated in randomized trials comparing adjuvant use of tamoxifen for 1--3 years with observation failed to show any impact of *PIK3CA* mutations on RFS among patients assigned to the observation arm (HR 0.62, 95% CI 0.25--1.59; *P*=0.32) ([Table 1](#t1-bctt-7-111){ref-type="table"}).[@b38-bctt-7-111] Similarly, another study that analyzed *PIK3CA* genotype in 342 tumors obtained from nonmetastatic lymph node-negative patients who had not had adjuvant therapy did not find any difference in metastasis-free survival between *PIK3CA*-mutant tumors and wild-type tumors ([Table 1](#t1-bctt-7-111){ref-type="table"}).[@b36-bctt-7-111]

#### Prognostic value for early breast cancer: overall survival

Study results show significantly more variation for OS than RFS. The wide variety of results may reflect the influence of postrecurrence treatment, which varies astronomically. As a reference, a meta-analysis of seven studies indicated that *PIK3CA* mutations had no prognostic impact on OS (HR 1.14, 95% CI 0.72--1.82; *P*=0.57).[@b30-bctt-7-111]

#### Prognostic value for advanced breast cancer

Unlike the case for early breast cancer, the prognostic value of *PIK3CA* mutations for advanced cases has not been studied extensively. One study evaluated the prognostic and predictive value of *PIK3CA* mutations in patients who received paclitaxel alone or in combination with lapatinib in a prospective randomized trial setting.[@b47-bctt-7-111] This study concluded that *PIK3CA* mutations were an adverse prognostic factor for survival, but were not predictive for lapatinib benefit.[@b47-bctt-7-111] This result should be interpreted with caution, because postprogression therapies with other anti-HER2 drugs might have affected subsequent patient outcome.

Potentially different prognostic value between exon 9 and 20 PIK3CA mutations
-----------------------------------------------------------------------------

Although both exon 9 and exon 20 hot-spot *PIK3CA* mutations were initially found to be gain-of-function and transforming mutations,[@b6-bctt-7-111],[@b7-bctt-7-111] more recent studies have noted differences in the protein partners required for PI3K activation and different tumorigenic potential in animal models between exon 9 and exon 20 mutations.[@b48-bctt-7-111],[@b49-bctt-7-111]

The possibility that clinical implications differ between these mutation sites remains controversial. One study demonstrated that patients with exon 9-mutant tumors were independently associated with early recurrence and death, whereas patients with exon 20-mutant tumors were associated with better prognosis than those with *PIK3CA* wild-type tumors.[@b32-bctt-7-111] Consistently, a recent study found that more exon 9-mutant patients experienced recurrence than exon 20-mutant patients (recurrence rate for exon 9 vs exon 20, 89% \[39 of 44\] vs 63% \[22 of 35\], *P*=0.007), while there was no difference in patient characteristics between the two sites of mutations.[@b34-bctt-7-111] Another study also showed that the RFS Kaplan--Meier curve for exon 20-mutant patients runs above that for exon 9-mutant patients, though the difference did not achieve statistical significance.[@b39-bctt-7-111] Collectively, these data suggest that exon 20 mutations might be a more favorable prognostic factor than exon 9 mutations, although further data collection is required to draw a definitive answer.

PI3K mutations in predicting the efficacy of systemic therapies
---------------------------------------------------------------

### Anti-HER2 therapies

Previous studies have suggested that the HER2/HER3/PI3K complex and subsequent PI3K--AKT signaling pathway was critical in *HER2*-amplified cells, and shown that disruption of this complex was a molecular mechanism of action of the anti-HER2 monoclonal antibody trastuzumab.[@b20-bctt-7-111],[@b21-bctt-7-111] Theoretically therefore, PI3K gain-of-function mutations were hypothesized to cause resistance to trastuzumab and other HER2-targeting drugs. A series of preclinical studies tested this hypothesis by transfecting wild-type and mutant forms of *PIK3CA* in *HER2*-amplified breast cancer cells.[@b50-bctt-7-111],[@b51-bctt-7-111] Results showed that mutant *PIK3CA* transfection resulted in resistance to trastuzumab or lapatinib, a small-molecule HER2 inhibitor.[@b50-bctt-7-111],[@b51-bctt-7-111] Consistent with these previous studies, our study using *HER2*-amplified breast cancer cell lines showed that cell lines with *PIK3CA* hot-spot mutations were significantly more resistant to trastuzumab and CL-387,785, a small-molecule HER2 inhibitor, than those without mutations.[@b52-bctt-7-111] However, another preclinical study using *HER2*-amplified breast cancer cell lines provided different conclusions. It showed that while *PIK3CA* mutations themselves did not correlate with in vitro resistance to either trastuzumab or lapatinib, *PIK3CA* mutations and/or PTEN-low cell lines as a group correlated with trastuzumab resistance, while still not affecting lapatinib sensitivity.[@b53-bctt-7-111]

#### Trastuzumab in early breast cancer: adjuvant setting

Several retrospective studies have supported the hypothesis generated by preclinical studies. A retrospective study analyzed the *PIK3CA* genotype in tumor samples from 240 HER2-positive early breast cancer patients who had been treated with cyclophosphamide, epirubicin, and fluorouracil followed by 1 year's trastuzumab in an adjuvant trial setting.[@b45-bctt-7-111] Results showed that patients with mutant *PIK3CA* had a shorter OS than those with wild-type *PIK3CA* (multivariate HR for OS 2.14, 95% CI 1.01--4.51; *P*=0.046), with no difference in DFS.[@b45-bctt-7-111] Similarly, in another study, the *PIK3CA* genotype was analyzed in samples obtained from 80 HER2-positive patients who participated in a Phase II study in which all patients received perisurgical chemotherapy consisting of anthracycline-based combinations and docetaxel and 1 year's trastuzumab. Results showed better DFS in patients with *PIK3CA* wild-type tumors than in those with *PIK3CA*-mutant tumors (HR for DFS 0.23, 95% CI 0.08--0.71; *P*=0.0063).[@b54-bctt-7-111]

However, studies from larger Phase III trials have produced different results. These studies were randomized trials that compared trastuzumab with no trastuzumab, which enables better distinction of the *PIK3CA* genotype as a prognostic factor from a predictive factor with regard to trastuzumab benefit, compared to studies where all patients received trastuzumab. In a biomarker study associated with the FinHER trial, a Phase III trial in which patients with *HER2*-amplified tumors were randomized to either 9 weeks' trastuzumab or control combined with chemotherapy, tumors were genotyped for 20 genes, including *PIK3CA*.[@b39-bctt-7-111] The study found no clear difference in benefit from trastuzumab therapy between *PIK3CA*-mutant and wild-type patients,[@b39-bctt-7-111] though the sample size was relatively small (total 157; *PIK3CA* wild-type 123, *PIK3CA*-mutant 34) and the duration of trastuzumab treatment was shorter than the current standard of 1 year.[@b39-bctt-7-111] More recently, a biomarker study evaluating the predictive value of the *PIK3CA* genotype in an adjuvant setting using 672 archived tumor samples from the National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 was reported.[@b55-bctt-7-111] NSABP B-31 was a randomized Phase III trial that compared doxorubicin/cyclophosphamide followed by paclitaxel with the same regimen combined with 1 year's trastuzumab starting from the paclitaxel phase.[@b55-bctt-7-111] Results showed that the DFS benefit from trastuzumab in *PIK3CA*-mutant tumors (HR 0.44, 95% CI 0.24--0.82; *P*=0.009) was similar to the benefit in *PIK3CA* wild-type tumors (HR 0.51, 95% CI 0.37--0.71; *P*=001),[@b55-bctt-7-111] suggesting a lack of predictive value for *PIK3CA* in trastuzumab efficacy, consistent with the FinHER trial.

Overall, it should be still considered inconclusive whether *PIK3CA* genotype has predictive value for a gain in DFS from adjuvant trastuzumab therapy ([Table 2](#t2-bctt-7-111){ref-type="table"}).

#### Trastuzumab in early breast cancer: neoadjuvant setting

Two recent large-scale studies evaluated the influence of *PIK3CA* genotypes on p-CR rate when trastuzumab was involved in neoadjuvant systemic therapy in HER2-positive patients. The first study evaluated the *PIK3CA* genotype in 504 tumor samples from participants in three independent neoadjuvant studies, in which all HER2-positive patients received either trastuzumab or lapatinib or this combination plus anthracycline--taxane chemotherapy.[@b56-bctt-7-111] Results showed that *PIK3CA* mutation was significantly associated with a lower p-CR rate (*PIK3CA*-mutant vs wild-type, 19.4% vs 32.8%, OR 0.49, 95% CI 0.29--0.83; *P*=0.008) in the overall population.[@b56-bctt-7-111] On classification by type of anti-HER2 therapy, p-CR rates in *PIK3CA*-mutant group were 16%, 24.3%, and 17.4% with lapatinib, trastuzumab, and their combination, respectively, and were 18.2%, 33.0%, and 37.1%, respectively, in the *PIK3CA* wild-type group. These results suggest that the influence of the *PIK3CA* genotype is greater in patients treated with trastuzumab-containing regimens than in those treated with lapatinib as the only HER2-targeted drug. Of note, this study did not find differences in DFS or OS between patients with mutant and wild-type *PIK3CA* ([Table 2](#t2-bctt-7-111){ref-type="table"}).[@b56-bctt-7-111]

The second biomarker study was accompanied by the NeoALTTO trial, a Phase III randomized neoadjuvant study of trastuzumab, lapatinib, or their combination in patients with early HER2-positive breast cancer.[@b57-bctt-7-111] Patients received anti-HER2 therapy for 6 weeks. Paclitaxel was then added to the regimen for a further 12-week period until definitive surgery.[@b57-bctt-7-111] The study produced similar results to those in the first study: a tendency for greater p-CR rates in *PIK3CA*-wild-type tumors than in wild-type tumors, particularly in the trastuzumab-containing group (p-CR rates with lapatinib, trastuzumab, and their combination of 14.8%, 20.0%, and 28.6%, respectively, in the *PIK3CA*-mutant group, and 20.4%, 28.4%, and 55.8%, respectively, in the *PIK3CA* wild-type group).[@b57-bctt-7-111] In terms of event-free survival and OS, the *PIK3CA* genotype again had no influence ([Table 2](#t2-bctt-7-111){ref-type="table"}).[@b57-bctt-7-111]

#### Trastuzumab in metastatic breast cancer

An initial study analyzing the *PIK3CA* genotype in tumor samples obtained from HER2-positive metastatic breast cancer patients who had undergone trastuzumab-based therapy showed an association between the presence of *PIK3CA* mutations and reduced time to progression (TTP).[@b50-bctt-7-111] Results of subsequent studies, however, were somewhat inconsistent, although not contradictory. A retrospective analysis of 137 HER2-positive breast tumor samples from patients who had been treated with trastuzumab-based therapies showed that *PIK3CA* mutation itself was not associated with the clinical benefit rate (CR + partial response \[PR\] + stable disease; *PIK3CA* wild-type vs mutant, 60% vs 58%; *P*=1.000), or OS (*P*=0.172).[@b28-bctt-7-111] However, the clinical benefit rate was significantly reduced in patients with *PIK3CA* mutations and/or PTEN loss (*P*=0.047).[@b28-bctt-7-111] In another retrospectively identified cohort of 139 patients with HER2-positive metastatic cancer treated with trastuzumab alone or in combination with chemotherapy, *PIK3CA* mutation was associated with increased risk of progression (HR 2.50, 95% CI 1.35--4.61; *P*=0.003), but not with OS. Multivariate analysis revealed PTEN loss and/or *PIK3CA* mutation as an independent single parameter associated with shorter TTP (HR 2.16, 95% CI 1.27--3.66; *P*=0.004) and reduced survival time from diagnosis of metastatic disease (HR 2.12, 95% CI 1.15--3.92; *P*=0.041).[@b29-bctt-7-111]

#### Lapatinib

The predictive value of the *PIK3CA* genotype for lapatinib is controversial from preclinical and clinical perspectives. In neoadjuvant lapatinib trials, as discussed earlier, the difference in clinical CR (c-CR) rate after lapatinib treatment between *PIK3CA*-mutant and wild-type groups was trivial.[@b56-bctt-7-111],[@b57-bctt-7-111] In a Phase II trial of lapatinib monotherapy in HER2-positive metastatic breast cancer, three *PIK3CA*-mutant patients were detected, and one durable PR and two stable disease responses were observed.[@b58-bctt-7-111] Considered together with the inconsistent preclinical findings,[@b53-bctt-7-111] the predictive value of the *PIK3CA* genotype for lapatinib may not be as high as that for trastuzumab ([Table 2](#t2-bctt-7-111){ref-type="table"}).

#### Pertuzumab

A biomarker study associated with the TRYPHAENA study, a randomized Phase II study comparing three treatment arms involving pertuzumab and trastuzumab in combination with chemotherapy, showed that patients carrying *PIK3CA* mutations tended to have a lower p-CR rate compared to patients with wild-type *PIK3CA*, although the difference did not reach statistical significance.[@b59-bctt-7-111] This finding indicates that the addition of pertuzumab may not be sufficient to overcome trastuzumab resistance caused by *PIK3CA* mutations.

The CLEOPATRA study was a randomized Phase III trial comparing docetaxel and trastuzumab with the same regimen combined with pertuzumab for first-line chemotherapy in HER2-positive recurrent or metastatic breast cancer patients.[@b60-bctt-7-111] Results of a biomarker study analyzing tumor samples obtained from these patients were recently published.[@b61-bctt-7-111] These showed that the addition of pertuzumab to trastuzumab resulted in an improvement in progression-free survival in both the *PIK3CA*-mutant and *PIK3CA* wild-type groups,[@b57-bctt-7-111] suggesting that the *PIK3CA* genotype does not predict a benefit from the addition of pertuzumab when trastuzumab is given as baseline treatment ([Table 2](#t2-bctt-7-111){ref-type="table"}).

### Endocrine therapies

Because *PIK3CA* mutations are most frequently found in ER-positive tumors, the question of whether these mutations cause resistance to endocrine therapies is of great interest. In in vitro studies, it was shown that PI3K and AKT can activate ER in the absence of estrogen, and constitutively active AKT causes tamoxifen resistance.[@b62-bctt-7-111] One study analyzed the correlation of the *PIK3CA* genotype and response to neoadjuvant endocrine therapy consisting of either tamoxifen, letrozole, or exemestane in three different clinical trials (n=235). Results showed that tumors with *PIK3CA* mutation tended not to respond to these therapies compared to those with wild-type *PIK3CA* (RR, *PIK3CA*-mutant \[exon 9\] vs *PIK3CA*-mutant \[exon 20\] vs *PIK3CA* wild-type, 14 of 25 \[56%\] vs 29 of 51 \[57%\] vs 111 of 159 \[70%\]; *P*=0.0459).[@b41-bctt-7-111] The aforementioned study involving tamoxifen and observation groups, however, failed to show a predictive value of *PIK3CA* mutation measured with RFS from adjuvant tamoxifen treatment.[@b38-bctt-7-111] Another study analyzing *PIK3CA* genotypes in tumors from 447 ER-positive metastatic patients who had undergone first-line tamoxifen treatment found no association of genotypes with treatment outcome measured by TTP.[@b36-bctt-7-111] On the other hand, patients with *PIK3CA*-mutant tumors treated with first-line aromatase inhibitors showed a longer TTP than patients with *PIK3CA* wild-type tumors, though the sample size was small (n=84).[@b36-bctt-7-111]

### Anti-PI3K pathway drugs

As of today, the mTOR inhibitor everolimus is the only drug targeting the PI3K pathway, which is indicated for breast cancer. While a preclinical study demonstrated that *PIK3CA* mutations can sensitize cells to everolimus,[@b63-bctt-7-111] clinical validation remains to be done. In addition to mTOR inhibitors, numerous inhibitors targeting molecules on the PI3K pathway are under preclinical and clinical development.[@b64-bctt-7-111] One study correlated the *PIK3CA* genotype and tumor response in patients who participated in Phase I studies of various PI3K/AKT/mTOR inhibitors.[@b65-bctt-7-111] Results showed that patients with a *PIK3CA* H1047R mutation had a higher PR rate than those with other *PIK3CA* mutations or wild-type *PIK3CA* treated under the same protocols (six of 16 \[38%\] vs five of 50 \[10%\] vs 23 of 174, \[13%\], respectively; *P*≤0.02).[@b65-bctt-7-111] Of note, RR in patients with exon 9 mutations was a mere 13.8%.[@b65-bctt-7-111]

Discussion
==========

Vigorous investigations of *PIK3CA* mutations in breast cancer have led to the carving of several matters in stone with a certain level of consistency. Namely, *PIK3CA* mutations 1) are most likely to be observed in ER-positive/HER2-negative tumors, 2) can coexist with other PI3K-enhancing mechanisms, such as *HER2* amplification and PTEN loss, 3) may potentially be a good prognostic marker, 4) may predict resistance to trastuzumab, and 5) do not guarantee a dramatic response to PI3K inhibitors.

In the clinic, prognostic biomarkers are used to select patients who have high risk for recurrence or relapse and thus need more potent treatment. As reviewed in this paper, many studies have found *PIK3CA* mutations to be good prognostic markers in patients with early breast cancer. However, it has to be emphasized that at this point *PIK3CA* should not be used to determine the intensity of systemic therapies for individual patients. This is because most studies that reported good prognostic impact of *PIK3CA* mutations were retrospectively conducted in a single hospital base, which limits their reliability and generalizability. In addition, most patients involved in these studies received certain systemic therapy, which precludes evaluation of prognostic biomarkers under their strict definition as "a marker that provides information on the likely course of the cancer disease in an untreated individual". In fact, two studies that retrospectively genotyped *PIK3CA* in patients untreated after surgery failed to show any prognostic impact of *PIK3CA* mutations.[@b32-bctt-7-111],[@b36-bctt-7-111]

On the other hand, predictive biomarkers can be used to select patients who are likely or unlikely to benefit from a certain treatment. Among studies conducted to evaluate the *PIK3CA* genotype as a predictive biomarker for various therapies, those involving trastuzumab-based therapies in the neoadjuvant setting provided the most consistent results: *PIK3CA* was associated with a lower p-CR rate.[@b56-bctt-7-111],[@b57-bctt-7-111] It is unclear, however, whether or not trastuzumab can be omitted in patients with HER2-positive/*PIK3CA*-mutant tumors, and a definitive answer will not be available in the future, because clinical trials employing a non-trastuzumab-containing arm are in effect impossible to conduct. Rather, the development of therapies to overcome trastuzumab resistance by *PIK3CA* mutations is awaited. One potential solution would be the combination of anti-HER2 drugs and PI3K-targeting drugs. Numerous PI3K-targeting drugs are under preclinical and clinical development, and HER2-positive/*PIK3CA*-mutant tumors are among their main targets.

Despite consistently lower p-CR rates in *PIK3CA*-mutant HER2-positive patients treated with trastuzumab-containing neoadjuvant therapies than in *PIK3CA* wild-type counterparts, no difference in DFS, a true end point for perisurgi-cal systemic therapy, was observed in large adjuvant or neoadjuvant trials between *PIK3CA*-mutant and wild-type patients. This is seemingly contradictory, based on two widely accepted postulations in breast oncology: that systemic therapy provides an identical impact on DFS regardless of the timing of the therapy given (neoadjuvant vs adjuvant), and that p-CR is associated with better prognosis thereafter. However, it is not definitely contradictory, for the following reasons. First, because neoadjuvant = adjuvant is a proven concept established by trials involving only chemotherapy, it may be inapplicable to targeted therapies. Recently, the ALLTO trial comparing trastuzumab and a trastuzumab plus lapatinib combination in an adjuvant setting failed to show an advantage for the combination in DFS, despite a higher p-CR rate in the identical combination arm in the NeoALTTO trial.[@b66-bctt-7-111] Second, while p-CR is consistently associated with a better prognosis after therapy on an individual patient basis, it was recently shown that impact on p-CR rate does not necessarily correlate with impact on DFS when analyzed on a trial basis.[@b67-bctt-7-111]

At the time of discovery of frequent *PIK3CA* somatic mutations in 2004,[@b3-bctt-7-111] which happened almost simultaneously with the development of clinically applicable PI3K inhibitors, it was expected that mutated PI3K would become a "home run" target, providing dramatic tumor regression when targeted, as had already been witnessed in *EGFR*-mutant lung adenocarcinoma and *KIT*-mutant gastrointestinal stromal tumors. However, the results of early clinical trials of various PI3K-targeting drugs suggested that this would not be the case ([Table 2](#t2-bctt-7-111){ref-type="table"}): RR was a mere 17% in *PIK3CA*-mutant tumors, albeit somewhat higher than in *PIK3CA* wild-type tumors.[@b65-bctt-7-111] As discussed in this review, *PIK3CA* mutations can be coobserved with other PI3K-enhancing molecular changes, such as *HER2* amplification and PTEN loss, which suggests that *PIK3CA* mutations themselves solely indicate a high level of cellular addiction to the pathway. In addition, adaptive compensative responses after inhibition of one pathway have been revealed to be important, so combination therapies targeting multiple signaling axes may be one way to maximize the effect.

Conclusion
==========

In conclusion, there is presently no sufficient evidence to support the clinical usefulness of *PIK3CA* genotyping in daily practice. Given that *PIK3CA*-mutant breast cancer appears to have distinct tumor biology, the development of more individualized targeted therapies, such as a combination of two or more targeted drugs, based on *PIK3CA* genotype is awaited.
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![Structure of class IA PI3K. Class IA PI3Ks are heterodimers consisting of p110 and p85 subunits. There are three p110 catalytic isoforms: p110α, p110β, and p110δ. The p110 isoforms share five distinct domains: an amino-terminal p85-binding domain (p85 BD), an RAS-binding domain (RAS BD), a putative membrane-binding domain (C2), the helical domain, and the carboxy-terminal kinase catalytic domain. There are also three p85 isoforms: p85α (and its splice variants p55α and p50α), p85β, and p55γ. They share three core domains, including a p110-binding domain called the inter-Src homology 2 (iSH2) domain, along with two SH2 domains. The two longer isoforms, p85α and p85β, have an SH3 domain and a BCR homology domain (BHD) located in their extended N-terminal regions.](bctt-7-111Fig1){#f1-bctt-7-111}

![Class I PI3K pathway. RTK activation allows p85 to interact with RTK directly or via adaptor proteins, which recruits PI3K to the membrane. On the cell membrane, inhibitory regulation of p85 to 110 is canceled, and PI3K becomes active as a kinase. Subsequently, PI3K catalyzes the conversion of PIP~2~ to PIP~3~. PTEN catalyzes the conversion of PIP~3~ to PIP~2~. PIP~3~ is further recognized by AKT and PDPK1. The connection of PIP~3~ to PDPK1 and AKT allows the physical interaction of PDPK1 and AKT, which leads to activation of AKT by phosphorylation of the T308 residue. For maximal activation of AKT, phosphorylation of the S473 residue by mTORC2 is required. AKT phosphorylates GSK3, FOXO1, MDM2, BIM, and BAD. AKT also phosphorylates and inactivates TSC2, which subsequently allows RHEB to activate mTORC1.](bctt-7-111Fig2){#f2-bctt-7-111}

![Difference between prognostic and predictive biomarkers.](bctt-7-111Fig3){#f3-bctt-7-111}

###### 

Studies evaluating prognostic impact of *PIK3CA* mutations with recurrence-free survival (RFS) as end point

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                  n     Systemic therapy   Mutation-analysis methods   Sequenced exons of *PIK3CA*     Median follow-up time (months, range)   Number of *PIK3CA*-mutant patients (%)           Median RFS (wt vs mt) (*P*-value)                       5-year RFS (%, wt vs mt) (*P*-value)   HR (as 1.0 for wt) (95% CI) (*P*-value)   
  ---------------------------------------- ----- ------------------ --------------------------- ------------------------------- --------------------------------------- ------------------------------------------------ ------------------------------------------------------- -------------------------------------- ----------------------------------------- ----------------------------------------
  Kalinsky et al[@b33-bctt-7-111]          590   NR                 MA + DS                     1--20                           153.6                                   Exon 9\                                          54 (9.2)\                                               NR\                                    NR\                                       NR\
                                                                                                                                                                        Exon 20\                                         88 (15.7)\                                              NR\                                    NR\                                       NR\
                                                                                                                                                                        Other\                                           50 (8.9)\                                               NR\                                    NR\                                       NR\
                                                                                                                                                                        Any                                              192 (32.5)                                              NR                                     NR                                        \<1 (*P*=0.06)

  Loi et al[@b39-bctt-7-111]               687   E, CTx, T-mab      MA                          1, 2, 4, 9, 13, 18, and 20      62                                      Exon 9\                                          61 (8.9)\                                               NR\                                    NR\                                       NR (*P*=0.64)\
                                                                                                                                                                        Exon 20\                                         100 (14.6)\                                             NR\                                    NR\                                       NR (*P*=0.48)\
                                                                                                                                                                        Other\                                           15 (2.2)\                                               NR\                                    NR\                                       NR\
                                                                                                                                                                        Any[\*](#tfn1-bctt-7-111){ref-type="table-fn"}   174 (25.3)                                              NR                                     NR                                        0.85 (0.57--1.28) (*P*=0.44)

  Stemke-Hale et al[@b23-bctt-7-111]       157   E                  MA                          23 known mutations              NR                                      Exon 9\                                          37 (6.8)[\^](#tfn2-bctt-7-111){ref-type="table-fn"}\    NR\                                    NR\                                       NR (*P*=0.64)\
                                                                                                                                                                        Exon 20\                                         73 (13.3)[\^](#tfn2-bctt-7-111){ref-type="table-fn"}\   NR\                                    88.10 vs 86.20 (*P*=0.799)\               NR (*P*=0.48)\
                                                                                                                                                                        Other\                                           7 (1.3)[\^](#tfn2-bctt-7-111){ref-type="table-fn"}\     NR\                                    NR\                                       NR\
                                                                                                                                                                        Any                                              117 (21.4)[\^](#tfn2-bctt-7-111){ref-type="table-fn"}   NR                                     88.10 vs 86.20 (*P*=0.919)                NR

  Gonzalez-Angulo et al[@b40-bctt-7-111]   347   E, CTx             MA                          9 and 20                        50.4                                    Exon 9\                                          23 (6.6)\                                               NR\                                    NR\                                       NR\
                                                                                                                                                                        Exon 20\                                         55 (15.6)\                                              NR\                                    NR\                                       NR\
                                                                                                                                                                        Any                                              78 (22.5)                                               NR                                     NR                                        NS (NR)

  Maruyama et al[@b31-bctt-7-111]          188   E, CTx             DS                          1, 2, 4, 7, 9, 13, 18, and 20   64                                      Exon 9\                                          17 (9.0)\                                               NR\                                    NR\                                       NR\
                                                                                                                                                                        Exon 20\                                         29 (15.4)\                                              NR\                                    NR\                                       NR\
                                                                                                                                                                        Other\                                           8 (4.3)\                                                NR\                                    NR\                                       NR\
                                                                                                                                                                        Any                                              54 (28.7)                                               NR                                     NR                                        0.42 (0.20--0.91) (*P*=0.03)

  Pérez-Tenorio et al[@b27-bctt-7-111]     270   E, CTx             SSCP + DS                   9 and 20                        132                                     Exon 9\                                          30 (11.1)\                                              NR\                                    NR\                                       NR\
                                                                                                                                                                        Exon 20\                                         36 (13.3)\                                              NR\                                    NR\                                       NR\
                                                                                                                                                                        Any                                              66 (24.4)                                               NR                                     NR                                        NS (NR)

  Hashimoto et al[@b43-bctt-7-111]         75    CTx                PCR-ARMS                    9 and 20                        63.2                                    Exon 9\                                          11 (14.7)\                                              NR\                                    NR\                                       NR\
                                                                                                                                                                        Exon 20\                                         15 (20.0)\                                              NR\                                    NR\                                       NR\
                                                                                                                                                                        Any                                              26 (34.7)                                               NR                                     NR                                        (EFS) 0.77 (0.33--1.78) (*P*=0.54)

  Abramson et al[@b34-bctt-7-111]          151   NR                 SNapShot                    9 and 20                        NR                                      Exon 9\                                          14.1%[ψ](#tfn3-bctt-7-111){ref-type="table-fn"}\        NR\                                    NR\                                       NR\
                                                                                                                                                                        Exon 20\                                         11.2%[ψ](#tfn3-bctt-7-111){ref-type="table-fn"}\        NR\                                    NR\                                       NR\
                                                                                                                                                                        Any                                              25.3%[ψ](#tfn3-bctt-7-111){ref-type="table-fn"}         145 vs 220 weeks (*P*=0.04)            NR                                        NR

  Cizkova et al[@b35-bctt-7-111]           452   E, CTx             DS                          9 and 20                        NR                                      Exon 9\                                          64\                                                     NR\                                    NR\                                       NR\
                                                                                                                                                                        Exon 20\                                         86\                                                     NR\                                    NR\                                       NR\
                                                                                                                                                                        Any                                              151 (one has both)                                      NR                                     (MFS) 69.6 vs 81.0 (*P*=0.0056)           0.62 (0.44--0.87)

  Cizkova et al[@b54-bctt-7-111]           80    CTx, T-mab         DS                          9 and 20                        51                                      Exon 9\                                          4 (5.0)\                                                NR\                                    NR\                                       NR\
                                                                                                                                                                        Exon 20\                                         13 (16.3)\                                              NR\                                    NR\                                       NR\
                                                                                                                                                                        Any                                              17 (21.3)                                               NR                                     NR                                        0.23 (0.08--0.71) (*P*=0.0063)

  Ellis et al[@b41-bctt-7-111]             153   E                  DS                          9 and 20                        NR                                      Exon 9\                                          18 (11.8)\                                              NR\                                    NR\                                       NR (NS)\
                                                                                                                                                                        Exon 20\                                         29 (17.8)\                                              NR\                                    NR\                                       \<1 (vs wt and exon 9 mt) (*P*=0.025)\
                                                                                                                                                                        Any                                              45 (29.4)                                               NR                                     NR                                        NR

  Beelen et al[@b38-bctt-7-111]            136   None               MA                          9 and 20                        93.6                                    Exon 9\                                          76 (15.4)[\#](#tfn4-bctt-7-111){ref-type="table-fn"}\   NR\                                    NR\                                       0.49 (0.11--2.25)\
                                                                                                                                                                        Exon 20\                                         89 (18.1)[\#](#tfn4-bctt-7-111){ref-type="table-fn"}\   NR\                                    NR\                                       0.72 (0.24--2.19)\
                                                                                                                                                                        Any                                              161 (32.7)[\#](#tfn4-bctt-7-111){ref-type="table-fn"}   NR                                     NR                                        0.62 (0.25--1.59)

  Ramirez- Ardila et al[@b36-bctt-7-111]   342   None               SNapShot                    9 and 20                        NR                                      Exon 9\                                          28 (8.2)\                                               NR\                                    NR\                                       1.04 (0.57--1.90) (*P*=0.90) (MFS)\
                                                                                                                                                                        Exon 20\                                         55 (16.1)\                                              NR\                                    NR\                                       0.98 (0.63--1.54) (*P*=0.94) (MFS)\
                                                                                                                                                                        Any                                              83 (24.3)                                               NR                                     NR                                        NR

  Barbareschi et al[@b32-bctt-7-111]       163   E, CTx             SSCP + DS                   9 and 20                        NR                                      Exon 9\                                          24 (14.8)\                                              NR\                                    (DFS) 61 vs 77 (*P*=0.040)\               NR\
                                                                                                                                                                        Exon 20\                                         21 (12.9)\                                              NR\                                    (DFS) 100 vs 77 (*P*=0.010)\              NR\
                                                                                                                                                                        Any                                              45 (27.6)                                               NR                                     NR                                        (DFS) NR (NS)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Two patients had double mutations;

denominator 542 samples;

including metastatic cases;

including tamoxifen-treated patient.

**Abbreviations:** mt, mutant; wt, wild type; NR, not reported; NS, not significant; MA, MassArray; DS, direct sequence; SSCP, single-strand conformation polymorphism; PCR-ARMS, polymerase chain reaction amplification-refractory mutation system; RFS, recurrence-free survival; E, endocrine therapy; CTx, chemotherapy; T-mab, trastuzumab; EFS, event-free survival; MFS, metastasis-free survival; DFS, disease-free survival.

###### 

Summary of predictive value of *PIK3CA* mutations in clinical settings

  Class of drug                                       Anti-HER2 drugs                                                                                                                      Endocrine drugs                                                                                                   Anti-PI3K-pathway drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------
  Comment on predictive value of *PIK3CA* mutations   Studies from large Phase III trials found no predictive value of *PIK3CA* mutations regarding benefit from T-mab adjuvant therapy.   Two large-scale studies found association of *PIK3CA* mutations with poorer p-CR, but not with DFS, EFS, or OS.   Some studies found predictive value of *PIK3CA* mutations regarding greater risk of progression, but results were inconsistent.   Insufficient data for conclusion, but *PIK3CA* mutations were unlikely to predict benefit from lapatinib therapy.   Insufficient data for conclusion, but *PIK3CA* mutations were unlikely to predict benefit from P-mab when T-mab was given as baseline therapy.   Results are inconsistent between studies, drugs, or treatment settings.   *PIK3CA* mutations may be associate with higher response rate, but unlikely to guarantee dramatic response.

**Abbreviations:** T-mab, trastuzumab; MBC, metastatic breast cancer; P-mab, pertuzumab; p-CR, pathologic complete response; DFS, disease-free survival; EFS, event-free survival; OS, overall survival.
